Research
Hormonal
GLP-1 receptor agonists have assumed the primary role in treating obesity with significant weight loss.
Practitioners should consider GLP-1 receptor agonists as a treatment for obesity.
LimitedSupportsmedium confidence
The GLP-1 receptor agonists have assumed the primary role in treating obesity with significant weight loss.
Why this rating
The claim is based on expert opinion.
Source
Obesity and diabetes: the final frontier
Marc Rendell · Expert Review of Endocrinology & Metabolism · 2023
DOI 10.1080/17446651.2023.2168643
reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →